Brad Kline

Brad Kline, Ph.D. is the Senior Director of Research and Development at Navrogen Inc.  Prior to joining the Navrogen team, he was responsible for overseeing antibody discovery and development at Morphotek Inc. During his tenure at Morphotek, he oversaw the engineering and development of several experimental antibodies that advanced to clinical trials as well as published on the underlying biological mechanisms of humoral immuno-suppression.

read more

Steven Kyriakos

Steven Kyriakos is the Vice President of Finance and Operations of Navrogen Inc. Prior to Navrogen, he was the Executive Director of Accounting and Finance at Morphotek Inc., a private biopharmaceutical company specializing in the development of antibody-based therapies for cancer, which was acquired by Eisai, Co. Ltd. in 2007. From 2007 to 2018, he remained at Morphotek, a subsidiary of Eisai, and led its global financial operations.

read more

Luigi Grasso

Luigi Grasso, Ph.D. is the Sr Vice President, Chief Scientific Officer and co-founder of Navrogen Inc. Prior to co-founding Navrogen, he was Vice President, CSO and co-founder of Morphotek Inc., a private biopharmaceutical company specializing in the development of antibody-based therapies for cancer, which was acquired by Eisai, Co. Ltd. in 2007. From 2007 to 2018, he remained at Morphotek as VP and CSO and oversaw the global R&D of antibody and next gen antibody-based products for the treatment of various cancer indications.

read more

Nicholas C. Nicolaides

Nicholas C. Nicolaides, Ph.D. is the President, Chief Executive Officer and co-founder of Navrogen™ Inc., a biopharmaceutical company developing targeted therapies for the treatment of cancer and immune-related disorders. From 2000 to 2018 he was the President, Chief Executive Officer and co-founder of Morphotek® Inc., a biopharmaceutical company specializing in the development of first-in-class antibody based products for the treatment of cancer, inflammatory and infectious diseases. 

read more